Tag Archives: British Society for Heart Failure (BSH)

25in25 The meeting began with an update on the 25in25 initiative from BSH Chair-Elect Dr Lisa Anderson (St George’s University Hospital, London). This national quality improvement initiative, led by the BSH in collaboration with over 54 national and international healthcare organisations, has the goal of reducing heart failure deaths by 25% over the next 25 years. With already over one million people in the UK living with heart failure, a number which is expected to double by 2040, the ambitious initiative is eagerly awaited. In the UK alone this could translate to over 10,000 lives saved per year. A population health approach underpins th

Preparing for the next 25 years Opening the meeting, BSH Chair Professor Roy Gardner (University of Glasgow) spoke about the BSH‘s aim to reduce HF mortality by 25% in 25 years, which would need the bringing together of all stakeholders to improve: Prevention strategies Identifying those at risk Early accurate diagnosis Appropriate treatment In his speech, he encouraged us to be more ambitious for further progress, to raise awareness of HF, and to educate more widely to achieve further progress and benefit more patients. 25 Fellows for 25 years Table 1. The new British Society for Heart Failure Fellows John Baxter, Sunderland Lynd

Clinical trials update Heart failure (HF) management in the 21st century was discussed by Professor John McMurray (University of Glasgow). We are fortunate to have evidence-based medications for HF with reduced ejection fraction (HFrEF): angiotensin-converting enzyme (ACE) inhibitors, beta blockers, mineralocorticoid receptor antagonists (MRAs), angiotensin receptor-neprilysin inhibitors (ARNIs); and now the rise of sodium glucose co-transporter 2 (SGLT2) inhibitors. Key messages from two studies with SGLT2 inhibitors – dapagliflozin in DAPA-HF1 and empagliflozin in EMPEROR-Reduced2 are: SGLT2 inhibitors reduce the risk of HF hospitalisati

Advanced heart failure From a trainee’s perspective, recognising when a heart failure (HF) patient is entering into the advanced stages is critical and sets off “transplant alarm bells”. Dr Sai Bhagra (Royal Papworth Hospital, Cambridge) delivered a great talk on this spectrum of the disease, essentially defining this as a failure of optimal therapy, requiring escalating diuretics with the development of end-organ dysfunction. The 2018 European Society of Cardiology definition of advanced HF encompasses: severe symptom limitation severe cardiac impairment pulmonary/systemic congestion requiring intravenous diuretics or malignant arrhy

No content available